复合益生菌制剂"海生元"急性毒性试验研究

目的 :观察复合益生菌制剂“海生元”(HSY)及其核心成分 益生菌 (M9、T9)经两种途径给药的急性毒性反应 ,评价其安全性。方法 :以健康小鼠为对象 ,将HSY、M9、T9三种受试物按i.p(腹腔注射 )和p .o(口服灌胃 )两种给药方式进行急毒试验。每种给药方法分 5个剂量组。i.p小鼠用Bliss法测得受试物的LD50 和 95 %可信限 ,p .o小鼠用安全限度试验测得受试物的最大耐受量。 结果 :1)i.p法测得各受试物LD50 和 95 %可信限 :M9为 898.31mg/ml(770 .18～ 92 5 .79) ;T9为 185 6 .95mg/ml(15 2 1.4 8～ 2 0 10 .36 ) ;HSY为 76 0 5 .2 3mg/ml(6 980 .5 2～ 830 4 .11)。 2 )p .o法测得各受试物最大耐受量及耐受倍数 :健康小鼠最大耐受量分别为M9>4 0 0 0mg/ml,T9>6 0 0 0mg/ml,HSY >15 0 0 0mg/ml;最大耐受量倍数 (即耐受成人每日用量的倍数 )分别为 133倍、2 0 0倍和 5 0 0倍。结论 :HSY、M9、T9口服给药均非常安全。三种受试物比较 ,又以HSY安全程度最高。     

安神补脑液对大鼠长期毒性的观察

目的观察安神补脑液长期灌胃给药对大鼠所产生的毒性反应及严重程度,提供毒副反应的靶器官及其损害的可逆程度,确定无毒反应剂量,以评价安神补脑液长期用药的安全性,为拟定临床试验剂量及观察指标提供参考。方法 Wistar大鼠随机分为安神补脑液低、中、高剂量组(2.5、5、10 m L/kg)和溶剂对照组(灌服同容积蒸馏水2 m L/100 g),每组60只,雌雄各半,每天给药1次,每周给药6 d,连续26周。观察大鼠的外观行为、体重、摄食量,并分别于给药第13、26周末及四周恢复期结束进行血液学及血液生化学等各项指标检测及脏器系数、病理组织学检查。结果长期连续灌胃给予安神补脑液,对动物一般状态、行为活动和外观体征无明显不良影响;各剂量组的摄食量、体重、血液学及血液生化学指标与对照组比较无明显差别;给药3个月、6个月对动物各脏器组织位置、重量和脏器系数无不良影响,但部分脏器重量有所增加,各组动物脏器系数在正常范围内;病理结果显示对照组和安神补脑液高剂量组动物未见明显与给药相关的异常病理改变和毒性改变,恢复期停药后未见延迟性毒性,因此,中、低剂量组动物各脏器组织无需进行组织病理形态学检查。结论安神补脑液长期用药对大鼠未见明确的毒性反应,停药后亦无延迟性毒性反应,预期拟定的临床用药量为安全剂量。     

热感赛比斯坦颗粒毒理学实验研究

观察热感赛比斯坦颗粒对小鼠的急性和大鼠长期毒性反应。将热感赛比斯坦颗粒生药浸膏液干燥,粉碎,以最大浓度及小鼠最大给药体积对小鼠灌胃,进行最大耐受量试验,观察两周之内出现的急性毒性反应。采用SD大鼠分别给予37.50 g/(kg·d)、12.50 g/(kg·d)、3.75 g/(kg·d)药物灌胃,空白组给予同等体积的蒸馏水,进行长期毒性试验。在给药30 d、停药15 d测定生化、血象指标、脏器系数和各主要脏器病理切片。急性毒性试验测得小鼠最大耐受量为299.70 g/kg,无死亡现象,解剖后发现小鼠各主要脏器无肉眼可见病变。长期毒性试验给药及恢复期间各组大鼠体重无统计学差异。血液学、血生化及脏器系数检查,给药组与对照组之间个别指标有差异,无毒性意义。主要脏器的病理组织学检查,未见明显病理改变。本研究证明热感赛比斯坦颗粒临床成人拟用给药剂量远低于其毒性剂量,安全性良好。     

大鼠对乙酰柠檬酸三丁酯的安全耐受值测定

按体重将80只SD大鼠随机分为对照组,低、中、高剂量组,每组雌雄各10只。持续静脉给药观察4周后处死,观察体重、脏器系数、血液及生化指标以及病理切片。与对照组比较,各组大鼠体重无显著性差异(p0.05);高剂量组雄鼠脑、肺、胸腺脏器系数差异显著(p0.05),雌鼠肝、卵巢脏器系数有差异显著(p0.05);中高剂量组雌、雄鼠部分血液及生化指标差异显著(p0.05);病理切片观察,各组大鼠肝脏均出现脂变,中高剂量组大鼠附睾、大肠出现炎症,其他器官未见明显病理改变。中高剂量组ATBC溶液对大鼠有一定毒性,参考低剂量组给药浓度,大鼠对其安全剂量为500 mg/kg体重/d。     

菖远胶囊给大鼠长期大剂量用药的安全性评价

目的：研究菖远胶囊对大鼠长期大量用药后的安全性影响。方法：通过对大鼠连续灌胃菖远胶囊13周、26周和停药4周,分别与正常对照组比较血液、生化、病理学检查结果。结果：①菖远胶囊各剂量组给药后5～30 min动物自主活动有所减弱,30 min后自主活动逐渐恢复正常,各剂量组大小便颜色偏深,高剂量组比较明显,停止给药后,上述症状均恢复正常;②大鼠血液细胞学、生化学指标中有个别指标在给药初期（13周）出现明显差异,继续给药至26周,未见明显异常,停止给药后恢复正常;高剂量组动物体重有一定降低,个别脏器质量及指数增大,停药4周后均能恢复正常;病理检查结果示,菖远胶囊各剂量组主要脏器未见由药物引起的病理学改变;整个实验期间各组动物未见死亡;③大鼠长期给予菖远胶囊的安全剂量为4.0 g/kg。结论：菖远胶囊对动物的毒性较低,是值得开发的一个中药新药。     

转Cry1Ab-ma基因玉米对大鼠的亚慢性毒性研究

目的：研究转Cry1Ab-ma基因玉米对大鼠的亚慢性毒性。方法：初断乳Wistar大鼠140只,随机分为7组：转基因玉米高中低3个剂量组（60%、30%、15%）、亲本玉米高中低3个剂量组（60%、30%、15%）以及1个常规基础饲料对照组,每组20只,雌雄各半。动物2只1笼喂养,自由进食饮水,连续观察90 d。每周称量饲料量及大鼠体重,在试验中、末期采集大鼠尿液和血液进行尿常规、血常规和血生化分析。实验末期称重脏器并计算脏器体重比,最后对大鼠脏器进行病理组织学检查。实验末期称重脏器并计算脏器体重比,最后对大鼠脏器进行病理组织学检查。结果：90 d的实验期内,各组大鼠均未发现中毒死亡情况。转基因玉米组个别评价指标虽与亲本玉米对照组或常规基础饲料对照组存在统计学差异,但指标水平在文献报道正常范围和历史对照范围内,且均未发现有生物学意义的改变。各受检脏器未见与受试物相关的病理改变。结论：现有实验结果不能证实转Cry1Ab-ma基因玉米对大鼠有亚慢性毒性作用。     

新型乙酰胆碱酯酶抑制剂Bis(9)-(-)-Meptazinol的小鼠 和大鼠药代动力学研究

目的:研究新型乙酰胆碱酯酶(acetylcholinesterase,AChE)抑制剂Bis(9)-(-)-Meptazinol(B9M)在小鼠和大鼠体内的药代动力学、组织分布和排泄过程。方法:应用本课题组前期报道的大鼠血浆中B9M的LC-MS/MS定量方法:检测B9M皮下和静脉给药后小鼠血浆和脑组织中的含量,计算相应的药代动力学参数,测定B9M小鼠(1.5 mg/kg)和大鼠(1.0 mg/kg)皮下给药后不同时间点的组织分布和粪便、尿液中排泄量。结果:小鼠经皮下注射后,B9M可迅速进入血液(Tmax=0.25 h)血液中消除速度较慢(T_(1/2)=18.09h)绝对生物利用度为115.95%。皮下注射后,B9M在脑内的达峰时间和半衰期分别是8h和18.75h,生物利用度为44.67%。小鼠和大鼠皮下给药后广泛分布于各组织,以脾、肺、肾等血流量大的组织中分布最多。B9M从体内排泄迅速原型药物在小鼠和大鼠尿液和粪便中的排泄量低于3%。结论:皮下给药B9M在小鼠和大鼠体内具有易吸收、分布广泛、易排泄的特点药代动力学特征优良,是极具研发潜力的抗阿尔茨海默病(Alzheimer's disease,AD)新药。     

灵芝孢子油长期毒性试验研究

目的:观察灵芝孢子油对大鼠产生的长期毒性反应和严重程度,确定本品安全用药剂量。方法:按1.67g/kg、0.83g/kg和0.42g/kg三个剂量,连续灌胃给药4个月及停药1个月,观察测试大鼠体重、血液学、血液生化学、脏器系数及病理组织学变化。结果:大鼠体重减轻,高剂量组ALP、TG值升高,高、中剂量组MCH、CREA值升高。结论:灵芝孢子油长期用药的安全剂量建议为每日用量不大于0.42g/kg。     

中枢注射Nesfatin-1与Exendin(9-39)对大鼠摄食和胃肠动力调节的影响

目的:探讨下丘脑室旁核注射GLP-1R拮抗剂Exendin(9-39)对Nesfatin-1所致大鼠摄食和胃肠动力改变的影响及作用机制。方法:选择40只雄性Wistar大鼠,随机分成正常对照组(NC组)、Nesfatin-1组(NS组)、Exendin(9-39)组(ES组)、Nesfatin-1联合Exendin(9-39)组(NE组)。采用下丘脑室旁核(PVN)埋置套管并分别给予以上药物干预,干预前和干预后的12小时、24小时记录和比较各组大鼠的摄食、饮水及体重变化。2天后,采用甲基纤维素-酚红溶液灌胃法测各组大鼠胃排空率,实时荧光定量法(RT-PCR)检测下丘脑及胃组织GLP-1Rm RNA的表达。结果:与基础摄食量比较,NS组大鼠给药后12 h、24 h的摄食量减少(P0.05),NE组大鼠给药后12 h、24 h的摄食量减少(P0.05),但较NS组增加(P0.05);与基础饮水量比较,NS组、NE组给药后12 h饮水量减少(P0.05);与基础体重比较,NS组大鼠给药后12 h、24 h的体重降低(P0.05),NE组大鼠给药后12 h的体重降低(P0.05),但较NS组增加(P0.05);NS组大鼠给药后胃排空率较NC、NE组大鼠显著下降(P0.05),NS组大鼠下丘脑GLP-1Rm RNA的表达量较NC组增加(P0.05)。结论:中枢给予GLP-1R拮抗剂能减弱Nesfatin-1引起的摄食抑制、胃排空延迟及体重下降效应,Nesfatin-1可能通过与GLP-1的协同作用参与摄食及胃肠动力的调节。     

黄芪注射液的急性毒性和长期毒性试验

目的:测定黄芪注射液急性毒性和长期毒性反应.方法:小鼠静脉注射和腹腔注射黄芪注射液的急性毒性,大鼠腹腔注射黄芪注射液6 g/kg(d,14 g/kg(d和33g/kg(d的长期毒性(30 d).结果:黄芪注射液小鼠静脉注射和腹腔注射LD50分别为90.39g/kg和108.11g/kg,其95%可信限分别为87.57～93.31g/kg和102.90～113.58g/kg;大鼠连续注射30 d后,摄食量增加,体重增长一致,尿常规,血液学和血液生化测定指标均在正常范围,脏器系数和病理学检查无异常.结论:黄芪注射液对受试动物未见有明显急性和长期毒性作用.     

复合益生菌制剂"海生元"制备各阶段效力稳定性观察

目的 :检测复合益生菌制剂“海生元”制备储存各阶段益生菌的存活数量及其生物表型的稳定性 ,以判定该制剂的效力稳定性。方法 :在有效期内 (1年 ) ,每月定期随机取 5个“海生元”胶囊 ,按常规对M9(乳杆菌QJ4 0 5 )和T9(双歧杆菌QJ4 0 5 )两株益生菌进行活菌培养计数和菌种鉴定。结果 :(1)在常温保存条件下的一年效期内 ,制剂中的 2种益生菌 (M9和T9)存活数量略有下降趋势 ,但各次结果均符合产品的效力要求 (活菌数 >10 8/ g)。 (2 )M9和T9各次纯培养的形态学、生化反应模式及终末代谢产物气相色谱定量分析结果均分别符合其乳杆菌和双歧杆菌的菌种鉴定特征。结论 :复合益生菌制剂“海生元”在常温保存的 1年有效期内 ,可保持制剂中益生菌的活菌数量及稳定的生物表型特征 ,从而保证该制剂的效力稳定性和疗效要求。     

长期低剂量摄入烯草酮原药对大鼠的毒性作用

目的研究长期低剂量摄入烯草酮原药对大鼠的毒性作用,确定其最大无作用剂量,为安全生产及慢性毒性实验提供剂量参考。方法将80只SD大鼠（雌雄各半）按体重随机分为4组,分别为烯草酮原药14.9mg/kg.d体重组、89.6 mg/kg.d体重组、537.5 mg/kg.d体重和正常对照组。在实验结束后处死实验大鼠,同时检测血液学、血清生化、体重和脏器系数等指标,并对结果进行统计学处理。结果与结论烯草酮原药对雄、雌性大鼠经口染毒剂量为89.6 mg/kg.d体重及以上时,对大鼠有毒性效应;长期低剂量摄入烯草酮原药对大鼠最大无作用剂量为14.9 mg/kg.d体重。     

Studies on the anti-inflammatory and toxic effects of the stem bark of Khaya ivorensis (Meliaceae) on rats.

Khaya ivorensis A. Chev. (Meliaceae) is a common feature in anti-malarial recipe prescribed by African traditional medical practitioners. Investigations have proved that Khaya species possesses some level of anti-plasmodial activity. Anti-inflammatory and toxicity studies were carried out on this plant using the Ugo Basile model 7140 and routine toxicity study methods, respectively, on adult wistar rats. The brain, spleen, heart, liver and kidneys were examined for dismorphological features, following oral administration of the ethanolic extract of K. ivorensis at the daily dose levels of 1000, 500 or 125 mg/kg for 7, 14 and 7 days after cessation of drug administration. The study showed that tissue toxicity, especially neurotoxicity was dose dependent, similarly the anti-inflammatory effect. The toxicity appeared to be reversible at lower doses. The wide margin between the therapeutic and toxic dosages makes the extract a possible safe drug in the management of malaria.     

Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats

A novel oral form of salmon calcitonin (sCT) was recently demonstrated to improve both fasting and postprandial glycemic control and induce weight loss in diet-induced obese and insulin-resistant rats. To further explore the glucoregulatory efficacy of oral sCT, irrespective of obesity and metabolic dysfunction, the present study investigated the effect of chronic oral sCT treatment on fasting and postprandial glycemic control in male lean healthy rats. 20 male rats were divided equally into a control group receiving oral vehicle or an oral sCT (2?mg/kg) group. All rats were treated twice daily for 5 weeks. Body weight and food intake were monitored during the study period and fasting blood glucose, plasma insulin and insulin sensitivity were determined and an oral glucose tolerance test (OGTT) performed at study end. Compared with the vehicle group, rats receiving oral sCT had improved fasting glucose homeostasis and insulin resistance, as measured by homeostatic model assessment of insulin resistance index (HOMA-IR), with no change in body weight or fasting plasma insulin. In addition, the rats receiving oral sCT had markedly reduced glycemia and insulinemia during OGTT. This is the first report showing that chronic oral sCT treatment exerts a glucoregulatory action in lean healthy rats, irrespective of influencing body weight. Importantly, oral sCT seems to exert a dual treatment effect by improving fasting and postprandial glycemic control and insulin sensitivity. This and previous studies suggest oral sCT is a promising agent for the treatment of obesity-related insulin resistance and type 2 diabetes.     

Protective effect of Phyllanthus fraternus against mitochondrial dysfunction induced by co-administration of cisplatin and cyclophosphamide

The evolving role of mitochondria, in mediating chemotherapy-induced apoptosis motivated us for the studies described here. The combination of cisplatin and cyclophosphamide is widely used in treating various types of cancers. The purpose of our study was to understand the mechanism of the toxicity induced by the co-administration of cisplatin and cyclophosphamide, on mitochondrial bioenergetics, and to study the protective effect of prior administration of the medicinal plant extract Phyllanthus fraternus. Our results reveal that co-administration of cisplatin (12 mg/kg, i.p) and cyclophosphamide (150 mg/kg, oral) to wistar rats (100 g) significantly alters mitochondrial structure and hence function. The rate of mitochondrial respiration was decreased significantly with both NAD + and FAD-linked substrates. The respiratory control ratio, an index of membrane integrity and the P/O ratio, a measure of phosphorylating efficiency also were decreased significantly accompanied by elevation in the lipid peroxide levels in liver, kidney homogenate and liver mitochondria respectively. Also, the phospholipid content of the mitochondrial membrane, showed a significant decrease, indicating mitochondrial membrane changes. Prior administration of an aqueous extract of P. fraternus (100 mg/kg) to rats, showed protection on all parameters investigated. Administration of P. fraternus alone did not show any significant changes on mitochondrial membrane bioenergetics. Thus, we propose, that the toxic side effects of cisplatin ₊ cyclophosphamide, are due to a chain of interconnected events, within the mitochondrial inner membrane, ultimately leading to hepatotoxicity and nephrotoxicity. Further, our work also suggests that administration of aqueous extract of P. fraternus can enhance the therapeutic potential of anticancer drugs by reducing drug related toxicity.     

Curcumin‐galactomannosides mitigate alcohol‐induced liver damage by inhibiting oxidative stress,hepatic inflammation,and enhance bioavailability on TLR4/MMP events compared to curcumin

Alcoholic liver diseases are classified as one of the major reasons for worldwide morbidity and mortality. Curcuminoids exhibit a wide range of pharmacological activities that are beneficial for health, including hepatoprotective effects, but its clinical significance is limited due to poor oral bioavailability. In the present study, a novel formulation of curcumin as curcumin‐galactomannosides (CGM) with enhanced oral bioavailability alleviated alcohol‐induced liver damage in wistar rats with an increased potency compared to the unformulated natural curcuminoids (CM). Ethanol administration significantly elevated liver toxicity markers, lipid peroxidation and inflammatory markers with a simultaneous reduction in antioxidant defenses. Supplementation of CGM reversed all of the pathological effects of alcohol administration, almost close to the normal level, when compared with CM. Histopathology of liver tissue also confirmed the better protective effect of CGM, indicating the enhancement in antioxidant and anti‐inflammatory effects as a function of bioavailability.     

Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment or a cross-reactive homologous peptide.

The oral administration of S-antigen fragment (a synthetic peptide designated as peptide M and known to be uveitopathogenic for rat, guinea pig, and monkey) to Lewis rats prior to challenge with an emulsion of peptide M and CFA resulted in either a total or partial suppression of experimental autoimmune uveitis (EAU), a T cell-mediated autoimmune disease studied as a model for human uveitis and experimental autoimmune pinealitis (EPA). Both the clinical and histopathologic manifestations of the disease were suppressed in a dose-dependent manner. Pinealitis associated with EAU was also suppressed by the oral administration of peptide M. Additionally, ingestion of a fragment of baker's yeast (Saccharomyces cerevisiae) histone H3, which has five consecutive amino acids identical to peptide M and which has been found to be uveitopathogenic in Lewis rats, induced tolerance to either peptide M or synthetic histone H3 peptide. In addition, the proliferative response to peptide M was inhibited in peptide M-fed rats. The suppression of EAU and in vitro lymphocyte proliferative responses to peptide M were observed to be antigen specific, since oral feeding of a control protein (BSA) exerted no suppressive effect. Furthermore, the T cells isolated from the spleen and lymph nodes of animals rendered tolerant by oral administration of peptide M can transfer protection against EAU adoptively. These results demonstrate that the oral administration of an autoantigen or its homologous peptide initiates an antigen-specific cellular mechanism which may ameliorate EAU.     

Effect of sodium molybdate on cadmium-related testicular damage in adult male Wistar rats

BackgroundMolybdenum, as a trace element, has various pharmacological effects, including antioxidant, antiviral, anti-allergic, anti-osteoporosis, anti-tumor, anti-inflammatory, anti-diabetic, anti-obesity, and free radical-scavenging activities. This study aimed at investigating the sodium molybdate impacts on cadmium chloride (CdCl₂)-induced testicular toxicity in adult Wistar rats.MethodsThe impacts of oral administration of sodium molybdate (0.05, 0.1, 0.2, and 0.4 mg/kg) was evaluated in healthy and infertile animals. Animals were randomly assigned to nine groups, including healthy control, sodium molybdate alone, infertile control (3 mg/kg of CdCl₂), and sodium molybdate plus CdCl₂. Following 30 days of administration, animals were sacrificed for biochemical and histopathological assays.ResultsThe results indicated that administration of sodium molybdate to infertile rats significantly mitigated the cadmium impacts on sperm appearance, concentration, and motility parameters. Also, sodium molybdate reduced the production of malondialdehyde (MDA) and enhanced antioxidant enzymes activities in the testicular homogenates in rats; these findings were supported by histopathological examinations. Treatment with sodium molybdate significantly increased aquaporin-9 (AQP9) expression in the testicular tissues of infertile rats.ConclusionsThe current findings suggested that sodium molybdate performs as a strong protective agent from CdCl₂-related testicular toxicity in rats.     

Arctigenic acid,the key substance responsible for the hypoglycemic activity of Fructus Arctii

We have reported the antidiabetic activity of the total lignans from Fructus arctii (TLFA) against alloxan-induced diabetes in mice and rats. In this study, arctigenic acid was found to be the main metabolite in rat plasma detected by UPLC/MS and HPLC/MS/MS after oral administration of TLFA. For the first time, its hypoglycemic activity and acute oral toxicity were evaluated in Goto-Kakizaki (GK) rats, a spontaneous type 2 diabetic animal model, and ICR mice respectively.GK rats were orally given arctigenic acid (50 mg/kg) twice daily before each meal for 12 weeks. The treatment reduced the elevated plasma glucose, glycosylated hemoglobin and showed significant improvement in glucose tolerance in glucose fed hyperglycemic GK rats. We found that the hypoglycemic effect of arctigenic acid was partly due to the stimulation on insulin secretion, whereas the body weight was not affected by arctigenic acid administration in GK rats. Meanwhile, there was no observable acute toxicity of arctigenic acid treatment at the dosage of 280 mg/kg body weight daily in the acute 14-day toxicity study in mice.This study demonstrates that arctigenic acid may be the main metabolite in the rat serum after oral administration of TLFA, which showed significant hypoglycemic effect in GK rats, and low acute toxicity in ICR mice. The result prompts us that arctigenic acid is the key substance responsible for Fructus Arctii antidiabetic activity and it has a great potential to be further developed as a novel therapeutic agent for diabetes in humans.